Promising Potential in Perspective Therapeutics' VMT-alpha-NET Program Amid Market Hesitations
Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors
Perspective Therapeutics Shares Are Trading Lower. The Company Announced Initial Results From Its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET.
Express News | Perspective Therapeutics Inc : Wedbush Cuts Target Price to $11 From $20
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Express News | Amex Halt Add Info Lst 3.400000